Full-Time
Updated on 9/4/2026
Global asset management for institutional clients
$90k - $180k/yr
Company Historically Provides H1B Sponsorship
Boston, MA, USA
Hybrid
Four days in the office and one day working remotely each week.
Bachelor's
See people who can refer or advise you
Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.
Company Size
1,001-5,000
Company Stage
N/A
Total Funding
$64.9B
Headquarters
Boston, Massachusetts
Founded
1933
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Comprehensive health coverage
Work-life balance
Financial future
Development
Clay, a New York-based startup selling AI tools for sales and marketing teams, has agreed to a new funding round led by Wellington Management at a $7 billion pre-money valuation, Axios reported on 31 August. The round's exact size has not been disclosed, and it is unclear whether it has fully closed. The valuation marks Clay's third jump in about a year, up from $3.1 billion in August 2025 and $5 billion in a January 2026 employee tender offer led by DST Global. The company was founded in 2017 by Kareem Amin and Nicolae Rusan. Clay markets itself as a go-to-market platform that pulls data from over 150 external sources and uses AI agents to research prospects and personalise outbound sales messages. Its customers reportedly include OpenAI, Anthropic, and Canva.
Muon Space closed a $250M Series C led by Eclipse Capital and joined by Google & Salesforce Ventures to scale constellation production....
Avere Therapeutics announced a $500 million private placement to advance AVR-001, its once-weekly oral IL-23 receptor antagonist for inflammatory diseases. Leading healthcare investors including Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, and Wellington Management participated in the funding round. Combined with a previously announced $320 million concurrent private investment, the proceeds will fully fund Avere's operations through 2029. The financing will close alongside Avere's merger with NextCure, expected in the second half of 2026. Upon completion, the combined company will operate as Avere Therapeutics and trade on Nasdaq under ticker symbol "AVRX." Avere is initially developing AVR-001 for psoriasis, with potential expansion into ulcerative colitis, Crohn's disease, and psoriatic arthritis.
The $545 million Series G nearly doubles Whatnot's valuation—a rare consumer-marketplace breakout at a moment when nearly every venture dollar is flowing to AI.
Tarsus Pharmaceuticals has secured $125 million through an oversubscribed private placement equity financing. The transaction includes participation from investors in Alkeus Pharmaceuticals, which Tarsus announced it would acquire earlier the same day. Notable investors include TCGX, Bain Capital Life Sciences, Wellington Management, ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital. The company is selling 2,098,519 shares of common stock at $56 per share and pre-funded warrants to purchase 133,625 additional shares. The financing is expected to close on 7 August 2026. Tarsus intends to use the proceeds to fund clinical development, commercial activities, and general corporate purposes. Barclays is serving as lead placement agent, with BofA Securities and William Blair as co-placement agents.